Get started
Author

Nina Keldsen

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
2012 · Kjell Magne Tveit, Tormod Guren, et al. · Journal of Clinical Oncology · 546
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
2013 · S. Kubicka, R. Greil, et al. · Annals of Oncology · 108
PDF
Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer
2010 · T K Bergmann, C Brasch-Andersen, et al. · The Pharmacogenomics Journal · 99
PDF
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer
2013 · M.K. Boisen, J.S. Johansen, et al. · Annals of Oncology · 88
PDF
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial
2013 · A. Johnsson, H. Hagman, et al. · Annals of Oncology · 77
Risk Factors for Central Nervous System Involvement in Non-Hodgkins-Lymphoma a multivariate analysis
1996 · Nina Keldsen, Wojciech Michalski, et al. · Acta Oncologica · 76
PDF
Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study
2003 · Nina Keldsen, Hanne Havsteen, et al. · Gynecologic Oncology · 55
A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX30 and chronomodulated XELOX30 as first-line therapy in patients with advanced colorectal cancer
2009 · C. Qvortrup, B.V. Jensen, et al. · Annals of Oncology · 51
PDF
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
2008 · B. Glimelius, H. Sørbye, et al. · Annals of Oncology · 47
Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
2014 · Mogens K. Boisen, Christian Dehlendorff, et al. · PLoS ONE · 44
PDF
Impact ofABCB1Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer
2011 · Troels K. Bergmann, Charlotte Brasch‐Andersen, et al. · Basic & Clinical Pharmacology & Toxicology · 42
Half body irradiation of patients with multiple bone metastases: A phase II trial
2008 · Randi S. Berg, Mette K. Yilmaz, et al. · Acta Oncologica · 34
PDF
Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type
2012 · Karina Dahl Steffensen, Marianne Waldstrøm, et al. · International Journal of Gynecological Cancer · 20
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer
2010 · C. Frederiksen, C. Qvortrup, et al. · Annals of Oncology · 20
PDF
Haematological effects from Radioiodine Treatment of Thyroid Carcinoma
1990 · N. Keldsen, B. T. Mortensen, et al. · Acta Oncologica · 19
PDF
Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP‐regimen): a phase II study
1991 · Peter Gimsing, Ole W. Bjerrum, et al. · British Journal of Haematology · 18
A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin
2010 · Mansoor Raza Mirza, Bente Lund, et al. · Gynecologic Oncology · 13
Oral Treosulfan as Second-Line Treatment in Platinum-Resistant Ovarian Cancer: A Phase II Study
1998 · Nina Keldsen, Ebbe Lindegaard Madsen, et al. · Gynecologic Oncology · 12
Oral idarubicin in elderly patients with acute myeloid leukemia
1990 · Nina Keldsen, Hans Karle, et al. · European Journal Of Haematology · 11
Translocations and deletions with breakpoint on 21q are nonrandomly associated with treatment-related acute nonlymphocytic leukemia and preleukemia
1987 · Nina Keldsen, Preben Philip, et al. · Cancer Genetics and Cytogenetics · 11
[Palliative medicine education].
2002 · Lise Pedersen, Anders Bonde Jensen, et al. · PubMed · 8
[Bone marrow depression due to 131I treatment of thyroid cancer].
1988 · N Keldsen, B T Mortensen, et al. · PubMed · 8
A phase II study of UFT and leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer
2004 · Niels Gyldenkerne, Bengt Glimelius, et al. · Acta Oncologica · 6
PDF
A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC).
2011 · A. Johnsson, J. Frodin, et al. · Journal of Clinical Oncology · 4
A 3-weekly schedule of irinotecan and panitumumab for wild-type KRAS metastatic colorectal cancer
2014 · Torben Fr⊘strup Hansen, Rikke Fredslund Andersen, et al. · Colorectal Cancer · 3
Works count: 53
Citation count: 1,439
H-index: 16
I10-index: 20
Year
Topic
Type